Kiniksa Pharmaceuticals International, plc
KNSAHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, Kiniksa Pharmaceuticals International, plc (KNSA) is listed under Drug Manufacturers - Specialty & Generic. The company carries a $5.90B market cap, placing it firmly in the mid-cap category. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Market Cap
$5.90B
Beta
0.04
P/E (TTM)
77.51
P/E (Fwd)
47.07
EPS (TTM)
$0.99
EPS (Fwd)
$1.63
ROE
14.0%
ROA
8.1%
Cash
$525.9M
Total Debt
$8.9M
Free CF
$126.1M
52W Change
89.0%
Annual Financials
Cash vs Debt
Where KNSA stands vs its 150-day and 200-day moving averages
As of the October 16, 2026 close, KNSA finished 27.78% above its 150-day moving average ($62.56) and 38.18% above its 200-day moving average ($57.85). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KNSA overbought or oversold?
At the October 16, 2026 close, KNSA's RSI(14) was 73.5, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Kiniksa Pharmaceuticals International, plc holds $525.9M in cash against $8.9M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $126.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 14.0% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.1% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $220.2M (2022) to $677.6M (2025), reflecting a 208% increase over the period.
KNSA's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Kiniksa Pharmaceuticals International, plc's trajectory.